Pfizer Targets Actavis Over Generic Lipitor

Law360, New York (August 13, 2010, 1:49 PM EDT) -- Pfizer Inc. has fired off a patent infringement suit seeking to block Iceland-based Actavis Group hf from launching a generic version of anti-cholesterol drug Lipitor.

New York-based Pfizer lodged its complaint in the U.S. District Court for the District of Delaware on Wednesday, after Actavis filed an abbreviated new drug application seeking federal approval to market atorvastatin calcium tablets, sold under the brand name Lipitor, before a patent covering the drug expires in January 2017.

The asserted patent, U.S. Patent Number 5,969,156, covers crystalline forms of...
To view the full article, register now.